Drug Development · global
Vir’s Hepatitis Delta Combination Meets Phase 3 Endpoint: 44% of Patients Achieve Undetectable Virus and Normal Liver Enzymes
The combination therapy given every four weeks showed signs of viral suppression, but comparing 48 weeks of treatment with week 12 in the delayed-treatment group cannot yet establish an advantage over existing drugs or demonstrate a reduction in long-term liver disease risk.
Chronic hepatitis delta can accelerate progression to cirrhosis and liver failure. The treatment challenge is to suppress the virus while reducing liver damage. On November 8, Vir Biotechnology announced preliminary results from the Phase 3 ECLIPSE 1 trial: after 48 weeks of combination treatment with elebsiran and tobevibart, 44% of patients achieved both undetectable hepatitis delta virus RNA and normalization of the liver enzyme ALT, meeting the primary endpoint.
The open-label, randomized trial enrolled 124 adults at 39 trial sites across 10 countries. According to HCPLive, 83 participants received subcutaneous injections of elebsiran 200 mg and tobevibart 300 mg every four weeks, while another 41 delayed treatment until week 12. The primary analysis compared results at week 48 in the treatment group with those at week 12 in the delayed-treatment group; 0% of the latter group met the endpoint. The difference between groups was statistically significant (p<0.0001), but the groups were not compared at the same follow-up time point.
The two drugs are designed to exploit the hepatitis delta virus’s dependence on hepatitis B surface antigen. Elebsiran is a small interfering RNA drug that reduces surface antigen production by degrading hepatitis B virus RNA; tobevibart is a monoclonal antibody that recognizes this antigen, designed to block viral entry into liver cells and promote the clearance of viral particles from the blood. The regimen requires sequential injections of the two drugs every four weeks.
Looking at the viral measure alone, 79% of patients in the treatment group achieved undetectable viral RNA at week 48, compared with 0% in the delayed-treatment group at week 12, also meeting the key secondary endpoint. Approximately 55% of participants already had compensated cirrhosis; in the treatment group, the proportions with undetectable virus were 85% among those with cirrhosis and 73% among those without it. This shows signs of viral suppression in both groups of patients, but does not support a conclusion that treatment is more effective in patients with cirrhosis, nor can undetectable virus be considered a cure.
On safety, the company reported one treatment-related Grade 3 decrease in neutrophil count, which resolved within 15 days, with no treatment interruptions or discontinuations reported. The most common treatment-related adverse events were flu-like symptoms, mostly occurring after the first dose and largely resolving within 24 to 48 hours. These data offer indications of tolerability over 48 weeks of treatment; less common or longer-term risks still require more patients and longer follow-up to clarify.
The findings released so far are preliminary primary results provided by the trial sponsor and presented at the annual meeting of the American Association for the Study of Liver Diseases. The open-label design, different assessment time points, and lack of an active-drug comparator all limit interpretation of the results. Improvements in viral RNA and ALT have also not yet directly demonstrated that the regimen can reduce liver cancer, liver failure, or death.
The next evidence will address clinical treatment choices more directly: ECLIPSE 2 is evaluating the effects of switching to the combination in patients whose virus remains insufficiently suppressed after bulevirtide treatment; ECLIPSE 3 is a direct comparison with bulevirtide. Vir expects results from both trials in the first quarter of 2027, then plans to combine the three studies for a submission to the U.S. Food and Drug Administration in mid-2027. This remains a submission plan; whether the therapy will be approved and the scope of its use depend on further data and regulatory review.